RxDoctor Payments Data

Kanan Hudhud, MD

Hematology & Oncology · Eden, NCNPI 1528069226

Payments from drug & device makers

$3,664in general payments, 2019–2025

Across 175 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$350
  • Johnson & Johnson$329
  • Astellas Pharma US Inc$313
  • Novartis$298
  • AstraZeneca$238
  • Sanofi$199
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$3,10285%
  • Education$56215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,664 in reported general payments places this provider in the 40th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$87,149
Medicare patients
417
Services billed
908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax33$332,297
CalquenceAcalabrutinib Maleate21$318,574
InlytaAxitinib16$317,138
Abiraterone Acetate81$275,572
RevlimidLenalidomide14$264,552
ImbruvicaIbrutinib15$237,445
XtandiEnzalutamide17$236,486
Lenalidomide16$211,072
EliquisApixaban56$44,193
XareltoRivaroxaban11$15,476
Letrozole82$1,346
Anastrozole85$1,114
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$1,053
Fentanyl16$938
Ondansetron OdtOndansetron61$826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta, Eliquis$98$361,33172 claims
AbbVieVenclexta$130$332,29733 claims
AstraZenecaCalquence$238$318,57421 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$62$275,57281 claims
Bristol Myers SquibbRevlimid$28$264,55214 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$69$237,44515 claims
Astellas Pharma US IncXtandi$313$236,48617 claims
Johnson & JohnsonXarelto$329$15,47611 claims
Lilly USA, LLCOlanzapine$64$29742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Eden

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →